Earlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world's first intranasal COVID-19 vaccine, has received approva...

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candid...

It may produce local antibodies in the upper respiratory tract - which could provide the potential to reduce infection and transmission.

According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...

According to the vaccine maker, it conducted two separate and simultaneous clinical trials to evaluate its intranasal vaccine (BBV154) as a...

"We will be applying for licenses and (they) should come. If everything goes well, we know by next month (August). You (people) would rathe...

The date of the meeting is yet to be fixed. India's drug controller had in January this year given permission to Bharat Biotech to conduct ...

The Central Drugs Standard Control Organization (CDSCO) has granted permission to the Christian Medical College, Vellore to conduct phase-I...

"Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce/stop transmission," the company said in a stat...

The trials of the Intranasal vaccine will take place at nine different sites of the country.

An intranasal vaccine as a booster dose would be easier to administer in mass vaccination campaigns and has the potential to prevent transm...

"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 part...

Bharat Biotech has come out with non-invasive vaccine, which is in the second phase of its trials. The second phase of the trial will be co...

BBV154 is the first intranasal Covid-19 vaccine to undergo human trials in India. It has now received approval to conduct Phase 2 randomise...

Early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be wel...

Most vaccines are administered by injection through intramuscular or subcutaneous route.

"Based on the safety and immunogenicity data of the phase 1 clinical trial, the company would be given permission for conducting phase 2 cl...